Overview

RV568 - Viral Challenge With RSV

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
RV568 is being developed for the treatment of diseases such as asthma, COPD and allergic rhinitis (e.g. hayfever). The main aim of this study is to investigate whether RV568 is effective in reducing the inflammation caused by viral infections such as RSV (respiratory syncytial virus).
Phase:
Phase 1
Details
Lead Sponsor:
Respivert Ltd